However, Nrf2 activation inhibited apigenin from activating PPARγ, suggesting a novel regulatory mode of apigenin for NAFLD (Feng et al., 2017). The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatotic liver disease.